Prevalence of Antiphospholipid Antibodies in Patients with Venous Thromboembolism at Chonburi Hospital
Keywords:
Antiphospholipid antibodies, Prevalence, Venous thromboembolism, Risk associationAbstract
Background: Venous thromboembolism (VTE) is a common condition in clinical practice. Antiphospholipid antibodies (APAs) have been investigated for the causes of thrombosis, which affect anticoagulant duration. The prevalence and association between VTE and APAs influenced the decision to investigate.
Objective: To investigate the prevalence and association between venous thromboembolism (VTE) and antiphospholipid antibodies (APAs).
Materials and Method: A retrospective cross-sectional study was conducted to analyze the medical records of patients with VTE at Chonburi Hospital from January 1, 2021, to April 30, 2024. The data collected included age, sex, body mass index (BMI), location of thrombosis, pregnancy status, underlying diseases, episodes of thrombosis, and presence of APAs. The binary logistic regression analysis focused on the prevalence and risk factors associated with APAs.
Result: In study of 189 venous thromboembolism patients, 42 (22.2%) tested positive for antiphospholipid antibodies. The average age was 46 years, with 54.8% being female. Multivariate analysis showed that these antiphospholipid antibody positive patients had a significant association with unprovoked thrombosis, with an adjusted odds ratio of 4.01 (p-value 0.03).
Conclusion: The prevalence of APAs in patients with VTE at Chonburi Hospital was 22.2%. The presence of APAs was significantly associated with unprovoked thrombosis. However, further studies are required to better understand this association.
References
Thai Society of Hematology. Guideline for Diagnosis and Treatment of Bleeding and Thrombosis. 2023; 117-195.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 (2): 295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995; 86 (10): 3685-91. https://doi.org/10.1182/blood.V86.10.3685.bloodjournal86103685
Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, et al. Deep venous thrombosis and lupus anticoagulant. Thromb Haemost. 1996; 76 (2): 187-9. https://doi.org/10.1055/s-0038-1650551
Eschwege V, Peynaud-Debayle E, Wolf M, Amiral J, Vissac A, Bridey F, et al. Prevalence of antiphospholipidrelated antibodies in unselected patients with history of venous thrombosis. Blood Coagul Fibrinolysis. 1998; 9 (5): 429-34. https://doi.org/10.1097/00001721-199807000-00005
Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus. 2003; 12 (2): 112-6. https://doi.org/10.1191/0961203303lu328oa
Paramsothy K, Wells PS. Prevalence of antiphospholipid antibodies in idiopathic venous thromboembolism. Blood. 2004; 104 (11): 529. https://doi.org/10.1182/blood.V104.11.529.529
Palomo I, Pereira J, Alarcon M, Vasquez M, Pinochet C, Vélez MT, et al. Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clin Rheumatol. 2004; 23: 129-33. https://doi.org/10.1007/s10067-003-0846-7
Deeb A, Hamdoun S, Dababo K. Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis. Iran J Immunol. 2009; 6 (3): 154-9.
Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18 (11): 2828-39. https://doi.org/10.1111/jth.15047
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018; 378 (21): 2010-21.
Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013; 368 (11): 1033-44. https://doi.org/10.1056/NEJMra1112830
Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood. 2010; 115 (4): 870-8. https://doi.org/10.1182/blood-2009-09-244426
Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8 (2): 237-42. https://doi.org/10.1111/j.1538-7836.2009.03674.x
De Laat B, Derksen RHWM, Reber G, Musial J, Swadzba J, Bozic B et al., An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of antibeta2- glycoprotein autoantibodies J Thromb Haemost. 2011; 9 (1): 149-53. https://doi.org/10.1111/j.1538-7836.2010.04068.x
Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathébras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2014; 13 (6): 595-608. https://doi.org/10.1016/j.autrev.2013.11.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Greater Mekong Subregion Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
